Current Oncology Reports

, Volume 7, Issue 3, pp 181–185

Adjuvant therapy for colon cancer

  • Weijing Sun
  • Daniel G. Haller
Article

Abstract

As there have been advances in the treatment of metastatic colorectal cancer, exciting developments have also been achieved in the adjuvant treatment of colon cancer. At the same time, more questions have been raised, and some controversies remain. The results of the MOSAIC trial demonstrated the benefit of adding oxaliplatin to 5-fluorouracil (5-FU) and leucovorin (FOLFOX) in adjuvant therapy for stage II and III disease, but the optimal duration of therapy and the management of toxicities remain to be resolved. Capecitabine is at least equivalent to the Mayo Clinic bolus 5-FU and leucovorin regimen in the adjuvant treatment of stage III colon cancer with a lower incidence profile of adverse events, allowing additional options for patients and physicians. Routine adjuvant systemic therapy in all patients with stage II colon cancer is still debatable. Although a statistically significant advantage for adjuvant treatment in stage II disease was shown for the first time from a large randomized study (QUASAR), the subsets of patients who truly benefit from therapy need to be identified. The application of pharmacogenetics and pharmacogenomics in adjuvant therapy for colorectal cancer will help to distinguish those patients with risk factors and to guide individualized therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics. CA Cancer J Clin 2004, 54:8–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Eisenberg B, Decosse JJ, Harford E, et al.: Carcinoma or the colon and rectum: the natural history reviewed in 1704 patients. Cancer 1982, 49:1131–1134.PubMedCrossRefGoogle Scholar
  3. 3.
    National Institute of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444–1450.CrossRefGoogle Scholar
  4. 4.
    Sun W, Haller D: Chemotherapy for colorectal cancer. Hematol Oncol Clin North Am 2002, 16:969–994.PubMedCrossRefGoogle Scholar
  5. 5.
    American Joint Committee on Cancer: AJCC Cancer Staging Manual, edn 6. New York: Springer; 2002:113–118. The revised new edition of TNM classification for carcinomas of colorectal cancer provides more detail than other staging systems.Google Scholar
  6. 6.
    Swanson RS, Compton CC, Stewart AK, et al.: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003, 10:65–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup trial INT-0089. J Clin Oncol 2003, 21:2912–2919. A detailed report concerning the number of lymph nodes analyzed for staging colon cancers as a prognostic variable on outcome.PubMedCrossRefGoogle Scholar
  8. 8.
    Compton CC, Fielding LP, Burgart LJ, et al.: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:979–994.PubMedGoogle Scholar
  9. 9.
    Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al.: Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998, 16:427–433.PubMedGoogle Scholar
  10. 10.
    Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247–257.PubMedCrossRefGoogle Scholar
  11. 11.
    Buyse M, Zeleniuch-Jaquotte A, Chalmers T, et al.: Adjuvant therapy of colorectal cancer: why we still don’t know. JAMA 1988, 259:3571–3578.PubMedCrossRefGoogle Scholar
  12. 12.
    Wolmark N, Fisher B, Colangelo L, et al.: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80:30–36.PubMedCrossRefGoogle Scholar
  13. 13.
    Laurie JA, Moertel CG, Fleming TR, et al.: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and 5-fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989, l7:1447–1456.Google Scholar
  14. 14.
    Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321–326.PubMedGoogle Scholar
  15. 15.
    Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993, 11:1879–1887.PubMedGoogle Scholar
  16. 16.
    Haller DG, Catalano PJ, Macdonald JS, et al.: Fluorouracil, leucovorin, and levamisole adjuvant therapy for colon cancer: Five-year final report of INT-0089 [abstract]. Proc ASCO 1998, 17:265a. This study made 6 to 7 months of 5-fluorouracil and leucovorin the standard adjuvant therapy for stage III colon cancer.Google Scholar
  17. 17.
    Andre T, Colin P, Louvet C, et al.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003, 21:2896–2903.PubMedCrossRefGoogle Scholar
  18. 18.
    Saini A, Norman AR, Cunningham D, et al.: Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003, 88:1859–1865.PubMedCrossRefGoogle Scholar
  19. 19.
    Saltz LB, Niedzwiecki D, Hollis D, et al.: Irinotecan plus fluorouracil/ leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803) [abstract]. J Clin Oncol 2004, 22:245s (A3500).CrossRefGoogle Scholar
  20. 20.
    Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2344–2351. This study demonstrated that adding oxaliplatin to 5-FU/LV improves the adjuvant treatment of colon cancer. Based on data from this study, the FDA approved oxaliplatin for adjuvant therapy in colon cancer treatment in combination with 5-FU/LV, making this regimen the new standard adjuvant therapy for stage III colon cancer.CrossRefGoogle Scholar
  21. 21.
    Sargent DJ, Wieand S, Benedetti J, et al.: Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials [abstract]. Proc ASCO 2004, 23:A3502.Google Scholar
  22. 22.
    http://en.sanofi-aventis.com/images/44_24731.pdf Accessed November 14, 2004.Google Scholar
  23. 23.
    Scheithauer W, McKendrick J, Begbie S, et al.: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003, 14:1735–1743.PubMedCrossRefGoogle Scholar
  24. 24.
    Cassidy J, Scheithauer W, McKendrick J, et al.: Capecitabine (X) vs. bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. J Clin Oncol 2004, 22:247s(A3509). This study shows the equivalence of oral fluoropyrimidine, capecitabine, and 5-FU/LV as adjuvant systemic therapy.CrossRefGoogle Scholar
  25. 25.
    Wolmark N, Wieand S, Lembersky B, et al.: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP Protocol C-06. J Clin Oncol 2004, 22:247s(A3508).Google Scholar
  26. 26.
    Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349–1355.PubMedGoogle Scholar
  27. 27.
    Piedbois P: Introduction, 4th International Conference on Colorectal Cancer in Paris. Semin Oncol 2001, 28(Suppl 1):1–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Marsoni S for IMPACT investigators: Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. Semin Oncol 2001, 28(Suppl 1):14–19.PubMedCrossRefGoogle Scholar
  29. 29.
    Benson III AB, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408–3419. This article addresses ASCO recommendations on adjuvant chemotherapy for stage II colon cancer based on 37 randomized controlled trials and 11 meta-analyses before QUASAR data were available.PubMedCrossRefGoogle Scholar
  30. 30.
    Gray RG, Hills BR, Hills R, et al.: QUASAR: A randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients [abstract]. Proc ASCO 2004, 23:A3501. This is the largest randomized trial for stage II colon cancer adjuvant therapy and the first to show statistically meaningful benefit of 5-FU-based adjuvant therapy.Google Scholar
  31. 31.
    Hikish T, Boni C, Navarro M, et al.: FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): subpopulation data from the MOSAIC trial [abstract]. Proc ASCO 2004, 23:A3619.Google Scholar
  32. 32.
    Gill S, Loprinzi CL, Sargent DJ, et al.: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004, 22:1797–1806. This study supplies model estimates of the magnitude of adjuvant therapy benefit across different subgroups. It may be useful for patients and physicians to assess the benefits and risks of adjuvant chemotherapy via a computer model at http://www.mayoclinic.com/calcs.PubMedCrossRefGoogle Scholar
  33. 33.
    Sargent DJ, Goldberg RM, Jacobson SD, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091–1097. This study demonstrated an equivalent benefit for adjuvant chemotherapy for elderly patients with localized colon cancer.PubMedCrossRefGoogle Scholar
  34. 34.
    Iwashyna TJ, Lamont EB: Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002, 20:3992–3998.PubMedCrossRefGoogle Scholar
  35. 35.
    Punt CJ, Nagy A, Douillard, et al.: Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002, 360:671–677.PubMedCrossRefGoogle Scholar
  36. 36.
    Fields AL, Keller AM, Schwartzberg L, et al.: Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study [abstract]. Proc ASCO 2002, 21:128a.Google Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Weijing Sun
    • 1
  • Daniel G. Haller
    • 1
  1. 1.Abramson Cancer CenterUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations